Case reveals IL-31 inhibition reduces pruritus and improves skin lesions in recessive dystrophic epidermolysis bullosa, suggesting immune activation involvement.
This case is intriguing in that selective inhibition of IL-31 led not only to rapid relief of severe pruritus but also to dramatic improvement of inflammatory skin lesions in pruriginosa-type RDEB. While IL-31 is well recognized as a central mediator of itch, this clinical course suggests that IL-31 functions as a disease-amplifying switch linking immune activation, scratching behavior, and cutaneous damage. Interrupting this pathway appeared to collapse the itch–scratch cycle itself, resulting in sustained clinical improvement beyond symptomatic itch control.
No takes yet. Share an insight, caveat, or question.
Ebi et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: